Edithistory:Mevrometostat
From EverybodyWiki Bios & Wiki
| oldid | date/time | username | edit summary |
|---|---|---|---|
| 1361895303 | 2026-06-30T18:45:12Z | Kowal2701 | [[WP:LLMPRV|Presumptive removal of LLM-generated content]], see [[Wikipedia:AI noticeboard/Archive 2#LLM edits by Noxoug1]]. Feel free to reinstate by following [[WP:LLMPRVOBJ|the procedures for disputing presumptive removal of LLM-generated content]]. |
| 1328743005 | 2025-12-21T16:53:38Z | Wolren | transparent image background |
| 1311938947 | 2025-09-17T19:14:38Z | Kvng | rm stub; [[Wikipedia:Database reports/Long stubs]]; [[Wikipedia:WikiProject Stub improvement]]; [[WP:STIM|you can help!]] |
| 1310944361 | 2025-09-12T13:18:05Z | Innerstream | |
| 1310835772 | 2025-09-11T21:37:45Z | Graeme Bartlett | added [[Category:Oxetanes]] using [[WP:HC|HotCat]] |
| 1310835753 | 2025-09-11T21:37:30Z | Graeme Bartlett | more ids |
| 1310835377 | 2025-09-11T21:33:54Z | Graeme Bartlett | added [[Category:Methoxy compounds]] using [[WP:HC|HotCat]] |
| 1310835341 | 2025-09-11T21:33:38Z | Graeme Bartlett | added [[Category:Lactams]] using [[WP:HC|HotCat]] |
| 1310835299 | 2025-09-11T21:33:19Z | Graeme Bartlett | added [[Category:Chloroarenes]] using [[WP:HC|HotCat]] |
| 1310835245 | 2025-09-11T21:32:58Z | Graeme Bartlett | added [[Category:Isoquinolines]] using [[WP:HC|HotCat]] |
| 1310835171 | 2025-09-11T21:32:25Z | Graeme Bartlett | added [[Category:Dihydropyridines]] using [[WP:HC|HotCat]] |
| 1310768321 | 2025-09-11T14:26:58Z | Boghog | consistent citation formatting |
| 1310726742 | 2025-09-11T07:23:43Z | Citation bot | Add: authors 1-19. | [[:en:WP:UCB|Use this bot]]. [[:en:WP:DBUG|Report bugs]]. | Suggested by Noxoug1 | #UCB_webform |
| 1310726517 | 2025-09-11T07:21:03Z | Noxoug1 | |
| 1310726430 | 2025-09-11T07:20:11Z | Noxoug1 | |
| 1310726104 | 2025-09-11T07:16:51Z | Noxoug1 | /* MEVPRO-1 study */ |
| 1310723402 | 2025-09-11T06:57:46Z | Noxoug1 | See also |
| 1310723290 | 2025-09-11T06:56:36Z | Noxoug1 | Regulatory status |
| 1310723237 | 2025-09-11T06:56:06Z | Noxoug1 | Pharmacokinetics |
| 1310723159 | 2025-09-11T06:55:12Z | Noxoug1 | /* Clinical development */ |
| 1310723126 | 2025-09-11T06:54:46Z | Noxoug1 | MEVPRO-2 |
| 1310723097 | 2025-09-11T06:54:13Z | Noxoug1 | MEVPRO-1 Study |
| 1310723019 | 2025-09-11T06:53:18Z | Noxoug1 | Side effects |
| 1310722927 | 2025-09-11T06:52:18Z | Noxoug1 | /* Key efficacy results */ |
| 1310722890 | 2025-09-11T06:51:57Z | Noxoug1 | Key efficacy results |
| 1310721988 | 2025-09-11T06:41:46Z | Noxoug1 | /* Phase I/II trials */ |
| 1310721935 | 2025-09-11T06:41:29Z | Noxoug1 | Phase I/II trials |
| 1310721704 | 2025-09-11T06:39:41Z | Noxoug1 | /* Mechanism of action */ expand |
| 1310721637 | 2025-09-11T06:39:19Z | Noxoug1 | /* Mechanism of action */ expand |
| 1310721562 | 2025-09-11T06:38:38Z | Noxoug1 | moa |
| 1310721503 | 2025-09-11T06:38:03Z | Noxoug1 | infobox |
| 1310721348 | 2025-09-11T06:36:51Z | Noxoug1 | create |
